and 5'-TCTCGAATTCTAGCCCCTTGAAGTCCGAGGCAGTAGGC-3' and the following 97-mer oligonucleotide templates [4] were used to amplify the mir30/shRNA target sequences:
Ren713 5'-TGCTGTTGACAGTGAGCG CAGGAATTATAATGCTTATCTATAGTG AAGCCACAGATGTATAGATAAGCATTATAATTCCTATGCCTACTGCCTCGGA-3' SK2(1) 5'-TGCTGTTGACAGTGAGCGACCGGTTGCTTCTATTGGTCAATAGTG AAGCCACAGATGTATTGACCAATAGAAGCAACCGGGTGCCTACTGCCTCGGA-3' SK2(2) 5'-TGCTGTTGACAGTGAGCGACGGCGCTAGGATTTGCACTAATAGTG AAGCCACAGATGTATTAGTGCAAATCCTAGCGCCGGTGCCTACTGCCTCGGA-3' SK2(3) 5'-TGCTGTTGACAGTGAGCGAAGGGTAGTGCCTGATCAATGATAGTG AAGCCACAGATGTATCATTGATCAGGCACTACCCTCTGCCTACTGCCTCGGA-3'. PCR products were digested with EcoRI and cloned into pTRIPZ(PL) to produce shRNA constructs pTRIPZ-Ren713 (negative control), pTRIPZ-SK2(1), pTRIPZ-SK2(2) and pTRIPZ-SK2(3) respectively. A triple shRNA containing vector, pTRIPZ-SK2(1-3), was then generated using blunt ClaI and MluI cassettes and ligated sequentially into pTRIPZ-SK2(1) and then pTRIPZ-SK2(1,2) following digestion with HpaI and MluI. Sequencing verified integrity and orientation of all the respective shRNA vectors.
Reagents and antibodies
The SK2 inhibitors, K145 [5] and ABC294640 [6] , were purchased from Medkoo Biosciences (Chapel Hill, NC). Bortezomib (Janssen Cilag, New Brunswick NJ) was kindly provided by the Royal Adelaide Hospital Pharmacy Department. Luciferin was purchased from Biosynth (Lake Constance, Switzerland). The following antibodies were purchased from Cell Signalling Technology (Berverly, MA): IRE1α, BiP, XBP1s, eIF2α, p-eIF2α (Ser51), CHOP, p-JNK (Thr183/Tyr185) and p-p38MAPK (Thr180/Tyr182). Antibodies to p-IRE1α (ser724) were purchased from Novus Biologicals (Littleton, CO). Antibodies to α-tubulin and β-actin were purchased from Abcam (Cambridge, MA). The following reagents were purchased from BD Biosciences (Franklin Lakes, NJ): Annexin-V FITC, 7-Aminoactinomycin (7AAD), anti-cleaved Caspase-3 FITC and Z-VAD-FMK. Propidium iodide (PI) was purchased from Sigma-Aldrich (St Louis, MO).
Western Blotting
Protein lysates of myeloma cell lines were obtained as previously described [2] and loaded into Criterion precast polyacrylamide gels (Bio-Rad, Hercules CA) prior to transferring onto nitrocellulose membranes. Membranes were incubated overnight with primary antibodies in 5% bovine serum albumen or 5% low-fat milk prior to incubation with HRP-conjugated secondary antibodies at room temperature for 2 to 3 h. Proteins were detected after the addition of Clarity ECL Substrate (BioRad) and chemiluminescence detected using the LAS-4000 imaging system (GE Healthcare Life Sciences, Little Chalfont UK). α-tubulin or β-actin were used as loading controls.
Generation of stably expressing tetracycline-inducible SK2 shRNA myeloma cell lines
Replication incompetent lentiviral particles were obtained after transient transfection of HEK293T cells using lipofectamine 2000 (Life Technologies, Carlsbad CA). Lentiviral supernatant was used to transduce human myeloma cell lines in the presence of 4 µg/mL polybrene for 72 h after which transduced cells were selected by the addition of 1 µg/mL puromycin to cultures.
Quantitative RT-PCR
RNA was extracted using the Qiagen RNEasy Mini Kit (Hilden, Germany) and cDNA obtained using the Qiagen Quantitect cDNA Synthesis Kit. Quantitative RT-PCR was performed on a Corbett Rotor-Gene 6000 thermal cycler (Corbett Life Science, Australia) using SYBR Green Real-time PCR Master Mix (Invitrogen, Carlsbad, CA) with thermal cycling conditions: 50 o C for 2', 95 o C for 2', 40 cycles of 95 o C for 15'', 60 o C for 15'' and a final melt of 55-95 o C. Products were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and analyzed on Rotor-Gene software using either quantitative or comparative quantitative analysis with the latter normalized to untreated control samples. The following primers were used: SK1 5'-TCTGGTGGTCATGTCTGGAG-3' and 5'-GACCTGCTCATAGCCAGCAT-3'; SK2 5'-TGGCAGTGGTGTAAGAACCA-3' and 5'-CAGTCAGGGCGATCTAGGAG-3'; XBP1u 5'-GGAGTTAAGACAGCG-3' and 5'-GTCAATACCGCCAGA-3'; XBP1s 5'-TGCTGAGTCCGCAGC-3' and 5'-GCTGGCAGGCTCTGG-3'; CHOP 5'-CAGAGCTGGAACCTGAGGAG-3' and 5'-TGGATCAGTCTGGAAAAGCA-3'; GAPDH 5'-AGCCACATCGCTCAGACAC-3' and 5'-GCCCAATACGACCAAATCC-3'.
Micro CT analysis
Computed tomography images were obtained using a SkyScan-1076 in vivo μCT scanner (Bruker MicroCT, Kontich Belgium) for a total of 18 mice preserved in formalin for this study. To remove soft X-rays, a 0.5 mm thick aluminium filter was placed in front of the X-ray source and the images were acquired at 48 kV and 110 μA with a scan resolution of 8.65 μm/ pixel. At each angular rotation step of 0.5 o , 1 image was acquired. Reference images without specimens were taken before each acquisition for flat field correction. Two-dimensional radiographic projection images were acquired as TIF files and reconstructed into BMP files using a cone-beam algorithm (NRecon Recontruction software, Bruker), with a beam hardening setting of 30% and ring artefact reduction of 10. The reconstructed BMP datasets were opened in Dataviewer (Bruker) and rotated in x-, y-and z-directions, to ensure that the volume of interest (VOI) to be created was in the correct position and angle. A new realigned dataset was then generated for each VOI and imported into CTAn software (Bruker). The top of the pelvis was identified and 1581 slices were selected and saved as a new VOI for analysis. Using the Batch Manager function within CTAn software, the VOIs were thresholded before 3D analysis was performed and a 3D model was generated. All images were viewed and edited using CTVol visualisation software (Bruker). In each VOI the following trabecular morphometric indices were assessed: Bone volume (mm 3 ), percent bone volume, tissue surface (mm 2 ), bone surface (mm 2 ), intersection surface (mm 2 ), bone surface/volume ratio (1/mm), bone surface density (1/mm), trabecular pattern factor (1/mm), structure model index, trabecular thickness (1/mm), trabecular number (1/mm), trabecular separation (1/mm).
Statistical analysis
Comparisons between two groups were performed using the Student t test or Kruskal-Wallis test (non-parametric) and between multiple groups using ANOVA analysis. The fractional product method [3] was used to discriminate between synergistic and antagonistic effects of drug combinations with a value of > 0.1 indicating antagonism and ≤ -0.1 indicating synergy. The effects of drug interactions were further evaluated by application of the combinatorial index using CompuSyn software (Paramus, NJ) with values < 1 indicating synergy. A multiple linear regression model was used to compare end-oftreatment differences in disease burden between groups of mice with inclusion of covariates to adjust for differences in sex and disease burden prior to commencing treatment (baseline). For survival studies, Kaplan-Meier analysis was performed and a log-rank test used to determine significance. Test statistics resulting in a P-value less than 0.05 were deemed significant. Statistical analyses were performed using Stata version 14 (StataCorp, College Station, TX). The indicated myeloma cell lines were cultured with increasing concentrations of K145 or ABC294640 (LP-1 cells) for 24 hours with or without 6 nM bortezomib (LP-1 cells), 2 nM bortezomib (H929 cells) and 4 nM bortezomib (5TGM1 cells). FP, fractional product (FP < -0.1 indicates a synergistic interaction). CI, combinatorial index (CI < 1 indicates a synergistic interaction). 
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